Medical Chemistry Small Molecule Treatment 
Drug Target Review
JUNE 16, 2025
DT-9046 is an orally delivered small molecule that has reached pre-IND studies – making Domain the first company to successfully advance a small molecule candidate targeting PAR2. Stephan holds a PhD in medical chemistry from University of Strasbourg in France.
Drug Target Review
JULY 18, 2025
Immuno-oncology has transformed cancer treatment, but for many patients, tumours remain resistant to even the most advanced immune checkpoint inhibitors. This opens the door for a disease-modifying approach both as a monotherapy and in combination, expanding treatment options and offering new hope to millions of patients.”
Expert insights. Personalized for you.
Let's personalize your content